Crossject, a pharmaceutical company specializing in emergency treatments, has published and made available its 2025 annual financial report. The report has been filed with the French financial markets authority and can be accessed on the company's website. This transparency supports investor confidence as Crossject continues developing its emergency epilepsy treatment, Zepizure. The release follows recent corporate updates including a new CFO appointment and confirmed financial progress in 2025.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
SEGG Media Corporation announced that Sports.com Predict will be the Official Prediction Partner for the 2026 UIM E1 World Championship, the first all-electric raceboat series. This partnership aims to enhance fan engagement by integrating real-time ...
In 2026, alternative ETFs have attracted nearly $30 billion in net new assets as investors seek diversification amid high market concentration and positive equity-to-bond correlations. Strategies like the iShares Systematic Alternatives Active ETF (I...
Cinthia Murphy of VettaFi highlighted on Yahoo! Finance that investors are increasingly choosing ETFs such as the ROBO Global Artificial Intelligence ETF (THNQ) to gain diversified exposure across the entire AI value chain. This approach helps mitiga...
Chase Sapphire Preferred updated its hotel credit benefit, doubling it from $50 to $100 while closing a loophole that let cardholders claim the credit without actually staying at a hotel by canceling bookings. Now, the $100 credit requires an actual ...
